S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
OTCMKTS:CYTR

CytRx News Headlines

$3.47
+0.29 (+9.12 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.82
Now: $3.47
$3.50
50-Day Range
$2.01
MA: $2.74
$4.15
52-Week Range
$0.35
Now: $3.47
$5.00
Volume121,226 shs
Average Volume180,429 shs
Market Capitalization$126.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12

Headlines

CytRx (OTCMKTS CYTR) News Headlines Today

Source:
SourceHeadline
CytRx Highlights Orphazymes Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C - Business WireCytRx Highlights Orphazyme's Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C - Business Wire
businesswire.com - March 5 at 12:58 AM
CytRx (OTCMKTS:CYTR) Shares Pass Above 200 Day Moving Average of $1.29CytRx (OTCMKTS:CYTR) Shares Pass Above 200 Day Moving Average of $1.29
americanbankingnews.com - March 5 at 12:18 AM
CytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type CCytRx Highlights Orphazyme’s Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
finance.yahoo.com - March 4 at 9:46 AM
CytRx to Participate in Upcoming Investor Conferences - Business WireCytRx to Participate in Upcoming Investor Conferences - Business Wire
businesswire.com - March 3 at 7:27 PM
CytRx to Participate in Upcoming Investor Conferences - Yahoo FinanceCytRx to Participate in Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - March 3 at 9:26 AM
CytRx to Participate in Upcoming Investor ConferencesCytRx to Participate in Upcoming Investor Conferences
finance.yahoo.com - March 3 at 9:26 AM
CytRx (OTCMKTS:CYTR) Share Price Passes Above Two Hundred Day Moving Average of $1.18CytRx (OTCMKTS:CYTR) Share Price Passes Above Two Hundred Day Moving Average of $1.18
americanbankingnews.com - February 25 at 2:52 AM
Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey OConnor Kolaja, to its Board of Directors - StreetInsider.comRevance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O'Connor Kolaja, to its Board of Directors - StreetInsider.com
streetinsider.com - February 23 at 12:58 AM
CytRx (OTCMKTS:CYTR) Share Price Passes Above 200-Day Moving Average of $1.08CytRx (OTCMKTS:CYTR) Share Price Passes Above 200-Day Moving Average of $1.08
americanbankingnews.com - February 17 at 2:21 AM
CytRx is Added to the LD Micro Index - Business WireCytRx is Added to the LD Micro Index - Business Wire
businesswire.com - February 12 at 10:33 PM
CytRx is Added to the LD Micro Index - Yahoo FinanceCytRx is Added to the LD Micro Index - Yahoo Finance
finance.yahoo.com - February 11 at 8:46 AM
CytRx is Added to the LD Micro IndexCytRx is Added to the LD Micro Index
finance.yahoo.com - February 11 at 8:46 AM
Kinase Inhibitors Market 2021 Competitive Status and Trend By Size till 2031 || Cytrx Corporation, Boehringer Ingelheim, Eton Bioscience Inc.Kinase Inhibitors Market 2021 Competitive Status and Trend By Size till 2031 || Cytrx Corporation, Boehringer Ingelheim, Eton Bioscience Inc.
marketwatch.com - February 9 at 2:53 PM
CytRx (OTCMKTS:CYTR) Stock Price Crosses Above 200-Day Moving Average of $1.00CytRx (OTCMKTS:CYTR) Stock Price Crosses Above 200-Day Moving Average of $1.00
americanbankingnews.com - February 9 at 2:28 AM
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients - Business WireCytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients - Business Wire
businesswire.com - January 15 at 2:06 PM
CytRx highlights positive data from phase 2 QUILT 88 trials in pancreatic cancer patients - Seeking AlphaCytRx highlights positive data from phase 2 QUILT 88 trials in pancreatic cancer patients - Seeking Alpha
seekingalpha.com - January 15 at 9:35 AM
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients - Yahoo FinanceCytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients - Yahoo Finance
finance.yahoo.com - January 15 at 9:00 AM
CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer PatientsCytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients
finance.yahoo.com - January 15 at 9:00 AM
CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C - Business WireCytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C - Business Wire
businesswire.com - December 31 at 6:19 PM
CytRx Comments on Proposed Combination of ImmunityBio and NantKwest - Yahoo FinanceCytRx Comments on Proposed Combination of ImmunityBio and NantKwest - Yahoo Finance
finance.yahoo.com - December 22 at 8:23 AM
CytRx Comments on Proposed Combination of ImmunityBio and NantKwestCytRx Comments on Proposed Combination of ImmunityBio and NantKwest
finance.yahoo.com - December 22 at 8:23 AM
CytRx Announces Orphazymes U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C - Business WireCytRx Announces Orphazyme's U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C - Business Wire
businesswire.com - December 7 at 9:08 AM
CytRx Comments on Quarterly Results and Recent Strategic Progress - Yahoo Finance AustraliaCytRx Comments on Quarterly Results and Recent Strategic Progress - Yahoo Finance Australia
finance.yahoo.com - November 16 at 8:26 AM
CytRx Comments on Quarterly Results and Recent Strategic Progress - Business WireCytRx Comments on Quarterly Results and Recent Strategic Progress - Business Wire
businesswire.com - November 16 at 8:14 AM
CytRx Comments on Quarterly Results and Recent Strategic ProgressCytRx Comments on Quarterly Results and Recent Strategic Progress
finance.yahoo.com - November 16 at 8:14 AM
CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C - Yahoo FinanceCytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C - Yahoo Finance
finance.yahoo.com - November 11 at 8:33 AM
CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type CCytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
finance.yahoo.com - November 11 at 8:33 AM
CytRx Highlights Orphazymes Acceleration of Pre-Launch Activities for Arimoclomol - Business WireCytRx Highlights Orphazyme's Acceleration of Pre-Launch Activities for Arimoclomol - Business Wire
businesswire.com - October 27 at 9:00 AM
CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for ArimoclomolCytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol
finance.yahoo.com - October 27 at 9:00 AM
Form S-8 CYTRX CORP - StreetInsider.comForm S-8 CYTRX CORP - StreetInsider.com
streetinsider.com - October 23 at 8:23 AM
CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment - Yahoo FinanceCytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment - Yahoo Finance
finance.yahoo.com - October 13 at 5:56 PM
CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer - Yahoo FinanceCytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer - Yahoo Finance
finance.yahoo.com - October 7 at 9:38 AM
CytRx Issues Statement Regarding Orphazymes Global Offering - Business WireCytRx Issues Statement Regarding Orphazyme's Global Offering - Business Wire
businesswire.com - September 30 at 1:24 PM
CytRx Issues Statement Regarding Orphazyme’s Global Offering - Yahoo FinanceCytRx Issues Statement Regarding Orphazyme’s Global Offering - Yahoo Finance
finance.yahoo.com - September 30 at 10:50 AM
Arrowhead Hits the Bullseye in Phase 2 Study of ARO-AAT; Analyst Targets Over 90% Upside - NasdaqArrowhead Hits the Bullseye in Phase 2 Study of ARO-AAT; Analyst Targets Over 90% Upside - Nasdaq
nasdaq.com - September 18 at 11:26 AM
CytRx Highlights Orphazymes Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C - Business WireCytRx Highlights Orphazyme's Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C - Business Wire
businesswire.com - September 17 at 9:37 AM
CytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type CCytRx Highlights Orphazyme’s Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C
finance.yahoo.com - September 17 at 9:37 AM
FDA accepts Orphazyme arimoclomol application for rare lipid disorder - Seeking AlphaFDA accepts Orphazyme arimoclomol application for rare lipid disorder - Seeking Alpha
seekingalpha.com - September 16 at 8:33 AM
CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation - Business WireCytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation - Business Wire
businesswire.com - September 4 at 1:02 AM
CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor PresentationCytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation
finance.yahoo.com - September 3 at 4:51 PM
Form 8-K CYTRX CORP For: Aug 21 - StreetInsider.comForm 8-K CYTRX CORP For: Aug 21 - StreetInsider.com
streetinsider.com - August 24 at 7:27 PM
CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities - Yahoo FinanceCytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities - Yahoo Finance
finance.yahoo.com - August 24 at 2:24 PM
CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic PrioritiesCytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities
finance.yahoo.com - August 24 at 9:24 AM
CytRxs Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign - Business WireCytRx's Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign - Business Wire
businesswire.com - August 13 at 8:51 AM
CytRx’s Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided CampaignCytRx’s Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign
finance.yahoo.com - August 13 at 8:51 AM
CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders - PRNewswireCytRx Files Definitive Proxy Statement and Sends Letter to Stockholders - PRNewswire
prnewswire.com - August 10 at 12:53 PM
CytRx Files Definitive Proxy Statement and Sends Letter to StockholdersCytRx Files Definitive Proxy Statement and Sends Letter to Stockholders
finance.yahoo.com - August 10 at 12:25 PM
CytRx Corporation Highlights Orphazymes Completion of Rolling Submission of its New Drug Application with the US FDA for Arimoclomol in Niemann-Pick Disease Type-C - PRNewswireCytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the US FDA for Arimoclomol in Niemann-Pick Disease Type-C - PRNewswire
www.prnewswire.com - July 21 at 7:52 PM
Arimoclomol application in U.S. fails to lift CytoRx - Seeking AlphaArimoclomol application in U.S. fails to lift CytoRx - Seeking Alpha
seekingalpha.com - July 21 at 9:58 AM
CytRx Corporation Highlights Orphazymes Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C - Yahoo FinanceCytRx Corporation Highlights Orphazyme's Completion of Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C - Yahoo Finance
finance.yahoo.com - July 21 at 9:47 AM
This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.